The role of the immune system in triple-negative breast cancer

被引:0
作者
Cvetka, Grasic Kuhar [1 ]
机构
[1] Onkol Inst Ljubljana, Zaloska Cesta 2, Ljubljana 1000, Slovenia
关键词
triple-negative breast cancer; PD-L1; tumour lymphocyte infiltration; immunotherapy; IMMUNOTHERAPY; STAGE; TILS;
D O I
10.25670/oi2020-006on
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The interaction between tumour and immune cells in tumour stroma is very important for the formation, development and progression of cancer. The most evaluated interactions are tumour lymphocyte infiltration (TIL) and programmed death ligand 1 (PD-L1) expression. Higher TIL density is an independent prognostic factor for the achievement of complete pathologic remission (pCR) after neoadjuvant systemic treatment in HER2-positive and triple-negative breast cancer. In triple-negative breast cancer, TIL is also prognostic for overall survival. Many studies with immunotherapy (checkpoint inhibitors) are ongoing in triple-negative breast cancer. In routine clinical practice, patients can be treated with atezolizumab+Nab-paclitaxel in primary metastatic breast cancer and those with progession after more than 12 months after the end of adjuvant treatment if their tumours express PD-L1. Many, studies addressing the mechanisms of the immune system and biomarkers are ongoing to reveal why only a subset of patients profit from immunotherapy.
引用
收藏
页码:32 / 38
页数:7
相关论文
共 50 条
[21]   Clinical trials of immunotherapy in triple-negative breast cancer [J].
Howard, Frederick M. ;
Pearson, Alexander T. ;
Nanda, Rita .
BREAST CANCER RESEARCH AND TREATMENT, 2022, 195 (01) :1-15
[22]   The clinical promise of immunotherapy in triple-negative breast cancer [J].
Vikas, Praveen ;
Borcherding, Nicholas ;
Zhang, Weizhou .
CANCER MANAGEMENT AND RESEARCH, 2018, 10 :6823-6833
[23]   The role of metabolic reprogramming in immune escape of triple-negative breast cancer [J].
Bao, Ruochen ;
Qu, Hongtao ;
Li, Baifeng ;
Cheng, Kai ;
Miao, Yandong ;
Wang, Jiangtao .
FRONTIERS IN IMMUNOLOGY, 2024, 15
[24]   The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC) [J].
Michaels, Elena ;
Chen, Nan ;
Nanda, Rita .
CLINICAL BREAST CANCER, 2024, 24 (04) :263-270
[25]   Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer [J].
Simmons, Christine E. ;
Brezden-Masley, Christine ;
McCarthy, Joy ;
McLeod, Deanna ;
Joy, Anil Abraham .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
[26]   Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review [J].
Serrano Garcia, Lucia ;
Javega, Beatriz ;
Llombart Cussac, Antonio ;
Gion, Maria ;
Perez-Garcia, Jose Manuel ;
Cortes, Javier ;
Fernandez-Murga, Maria Leonor .
FRONTIERS IN IMMUNOLOGY, 2024, 15
[27]   Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer [J].
Michel, Laura L. ;
von Au, Alexandra ;
Mavratzas, Athanasios ;
Smetanay, Katharina ;
Schuetz, Florian ;
Schneeweiss, Andreas .
TARGETED ONCOLOGY, 2020, 15 (04) :415-428
[28]   Current Status of Immune Checkpoint Inhibitors and Treatment Responsive Biomarkers for Triple-Negative Breast Cancer [J].
Wang, Xinran ;
Wang, Lingxia ;
Liu, Yueping .
THORACIC CANCER, 2025, 16 (09)
[29]   Immune-related biomarkers in triple-negative breast cancer [J].
Zhang, Juan ;
Tian, Qi ;
Zhang, Mi ;
Wang, Hui ;
Wu, Lei ;
Yang, Jin .
BREAST CANCER, 2021, 28 (04) :792-805
[30]   Immune-related biomarkers in triple-negative breast cancer [J].
Juan Zhang ;
Qi Tian ;
Mi Zhang ;
Hui Wang ;
Lei Wu ;
Jin Yang .
Breast Cancer, 2021, 28 :792-805